1888
Foundation of the Institute of Experimental Medicine, the first Russian scientific research institution in the field of medicine and biology.
1895
Launch of production of anti-diphtheria serum, which became the first serum therapeutic product in Russia.
1899
A laboratory was organized to study the plague and develop effective anti-plague vaccines and sera.
1917–1938
The Vaccine and Serum Department of the Institute of Experimental Medicine became the main supplier of vital immune drugs and the initiator of the infection diseases control.
1938
The Vaccine and Serum Department was separated into an independent scientific research institution – the Leningrad Scientific Research Institute of Vaccines and Sera (LenSRIVS), subordinate to the USSR Ministry of Health.
1941 – 1945
During the Great Patriotic War, the Institute continued its work, providing the front lines and rear areas with necessary immunobiological drugs, making its contribution to the common victory.
1946 – 1952
The post-war years became a period of active development for the Leningrad Scientific Research Institute of Vaccines and Sera (LenSRIVS).
1952
Launch of production of influenza vaccines and diagnostic agents under the leadership of scientist A.A. Smorodintsev.
1970 – 1976
Construction of a modern research and production complex in Krasnoe Selo.
1991
The Leningrad Scientific Research Institute of Vaccines and Sera is renamed the Saint Petersburg Scientific Research Institute of Vaccines and Sera (SPbSRIVS).
2006
Transformation of the Institute into a federal state unitary enterprise (FSUE), subordinate to the Federal Medical and Biological Agency (FMBA of Russia).
2007
Registration of the tuberculosis diagnostic agent “Purified tuberculosis allergen in standard dilution (purified tuberculin in standard dilution)” (Mantoux test).
2014
Launch of full-cycle production of influenza vaccines that meet international GMP standards, joining the international organizations IFPMA and IVC.
2015
The first Russian vaccine receives a marketing authorization in Latin America, which becomes an important step towards expanding the geography of exports.
2016
Start of construction of the joint Russian-Nicaraguan enterprise Instituto Latinoamericano de Biotecnología MECHNIKOV, S.A.
2016
SPbSRIVS becomes the only Russian enterprise supplying influenza vaccines to non-CIS countries, including the Republic of Cuba and Nicaragua.
2017
Joining the Developing Countries Vaccine Manufacturers Network (DCVMN).
2018
Registration of the original trivalent influenza vaccine “Flu-M”, which is superior to foreign analogues.
2019
Start of commercial production of the influenza vaccine at the site of Instituto MECHNIKOV, S.A., in the Republic of Nicaragua.
2020
WHO includes the first Russian development of SPbSRIVS in the list of candidate vaccines against COVID-19.
2020
SPbSRIVS enters the list of strategic enterprises of the pharmaceutical and medical industry.
2021
Registration of the quadrivalent influenza vaccine Flu-M Tetra, and establishment of a Research and Development Center with the support of the Government of the Russian Federation to create a new generation vaccine against COVID-19.
2022
Registration of the innovative vaccine “Convacell” against coronavirus infection.
2022
Completion of the modernization of the Influenza Preparations Production Area increasing the capacity to 35 million doses of the trivalent influenza vaccine per year.
2023
Successful completion of the WHO audit as part of the prequalification procedure for the Flu-M influenza vaccine and the Inactivated Split Influenza Vaccine (ISIV).
2023
Start of commercial deliveries of Convacell to the Republic of Nicaragua.
2023
First use of the Institute’s influenza vaccines in the Republic of Belarus for all age groups.
2024
Convacell receives a permanent marketing authorization.
2024
Obtaining a marketing authorization for the Baby-Hib vaccine against infection caused by Haemophilus influenzae type b.
2025
Obtaining a WHO prequalification status for the Flu-M influenza vaccine.
